Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 15/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865134 | 0.91 | MAP2K4 (0.51) | MAP2K4KITMAP2K7SLC22A12CSNK1D | |
| SCHEMBL2857629 | 0.84 | MAP2K4 (0.46) | MAP2K4KITCSNK1D | |
| SCHEMBL2869839 | 0.82 | MAP2K4 (0.61) | MAP2K4MAP2K7CSNK1DNTRK1 | |
| SCHEMBL2863255 | 0.81 | TTK (0.47) | MAP2K4MAP2K7NTRK1 | |
| SCHEMBL13636072 | 0.77 | HTR7 (0.44) | MAP2K4NTRK1 | |
| SCHEMBL2858263 | 0.74 | HTR7 (0.44) | MAP2K4 | |
| SCHEMBL2861586 | 0.73 | MAP2K4 (0.56) | MAP2K4 | |
| SCHEMBL2868379 | 0.71 | TTK (0.47) | MAP2K4MAP2K7NTRK1 | |
| SCHEMBL2859630 | 0.71 | HTR7 (0.44) | MAP2K4 | |
| SCHEMBL2863645 | 0.71 | TTK (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAP2K4 61/4885KIT 780/4885MAP2K7 31/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAP2K4 53/4885KIT 1467/4885MAP2K7 40/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAP2K4 61/4885KIT 780/4885MAP2K7 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.